直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 118258
タイトル別表記
血漿Heparin Cofactor II活性は2型糖尿病患者における非アルコール性脂肪性肝疾患肝線維化と逆相関する
Heparin Cofactor II and NAFLD in T2DM
著者
原, 倫世 徳島大学大学院医学研究科(医学専攻) 徳島大学 教育研究者総覧
Uemoto, Ryoko Tokushima University
Sekine, Akiko Tokushima University
Mitsui, Yukari Tokushima University
Masuda, Shiho Tokushima University
乙田, 敏城 Tokushima University
Honda, Soichi Minami Municipal National Insurance Hospital
Kondo, Akira Kondo Naika Hospital
キーワード
ヘパリンコファクターII
プロテアーゼ活性化受容体
糖尿病
NAFLD
横断研究
Thrombin
Protease-activated receptors
Heparin cofactor II
T2DM
資料タイプ
学位論文
抄録
Aims: Thrombin exerts various pathophysiological functions by activating protease-activated receptors (PARs), and thrombin-induced activation of PARs promotes the development of non-alcoholic fatty liver disease (NAFLD). Since heparin cofactor II (HCII) specifically inactivates thrombin action, we hypothesized that plasma HCII activity correlates with the severity of NAFLD.
Methods: A cross-sectional study was conducted. Plasma HCII activity and noninvasive clinical markers of hepatic fibrosis including fibrosis-4 (FIB-4) index, NAFLD fibrosis score (NFS) and aspartate aminotransferase-to-platelet ratio index (APRI) were determined in 305 Japanese patients with type 2 diabetes mellitus (T2DM). The relationships between plasma HCII activity and the clinical markers were statistically evaluated.
Results: Multiple regression analysis including confounding factors showed that plasma HCII activity independently contributed to decreases in FIB-4 index (p<0.001), NFS (p<0.001) and APRI (p=0.004). In addition, logistic regression analysis for the prevalence of advanced hepatic fibrosis defined by the cutoff points of the clinical scores showed that plasma HCII activity was the sole and common negative factor for prevalence of advanced hepatic fibrosis (FIB-4 index: p=0.002, NFS: p=0.026 and APRI: p=0.012).
Conclusions: Plasma HCII activity was inversely associated with clinical hepatic fibrosis indices including FIB-4 index, NFS and APRI and with the prevalence of advanced hepatic fibrosis in patients with T2DM. The results suggest that HCII can serve as a novel biomarker for assessment of hepatic fibrosis of NAFLD in patients with T2DM.
掲載誌名
Journal of Atherosclerosis and Thrombosis
ISSN
18803873
13403478
出版者
Japan Atherosclerosis Society
30
8
開始ページ
871
終了ページ
883
発行日
2023-08-01
備考
内容要旨・審査要旨・論文本文の公開
本論文は,著者Tomoyo Haraの学位論文として提出され,学位審査・授与の対象となっている。
権利情報
This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.( https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ja )
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
博士論文全文を含む
文科省報告番号
甲第3689号
学位記番号
甲医第1554号
学位授与年月日
2023-03-23
学位名
博士(医学)
学位授与機関
徳島大学
部局
医学系
病院
先端酵素学研究所
歯学系